CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Founded in 1991, CTI BioPharma based in Seattle, Wash., is a commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers.
CTI BioPharma's mission is to develop targeted therapies that provide meaningful changes in patients' lives.
CTI BioPharma's vision is to become a leading provider of novel targeted therapies that meet the demands of healthcare providers and patients.
Mr. James K. Fong (Exec. VP & Chief Commercial Officer)
Mr. Bruce K. Bennett Jr. (Sr. VP Global Pharmaceutical Operations)
Mr. John P. Volpone (Exec. VP & Chief of Staff)
Dr. Jennifer A. Smith (Sr. VP of Biometrics)
Recognition and Awards
CTI BioPharma has been recognized with a number of awards throughout its history, including the Washington Biotechnology & Biomedical Association's Pioneer of the Year award , the Fred Hutchinson Cancer Research Center's Visionary Award , and the American Cancer Society's Horizon Award .